GeneDx Holdings Corp.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M |
| Gross profit | $298.2M | $194.4M | $90.0M | -$26.8M | -$16.6M |
| Operating income | -$13.1M | -$23.2M | -$180.6M | -$667.7M | -$446.1M |
| Cost of revenue | $129.4M | $111.1M | $112.6M | $261.4M | $228.8M |
| Cash from operations | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M |
| Capital expenditure | $19.0M | $5.5M | $5.2M | $7.2M | $9.4M |
| Free cash flow | $14.3M | -$34.0M | -$185.4M | -$326.3M | -$199.8M |
| Impairments | $0 | $0 | $10.4M | $210.1M | $0 |
| Total assets | $523.7M | $419.4M | $418.8M | $490.9M | $554.1M |
| Total liabilities | $215.5M | $174.1M | $190.7M | $237.2M | $166.0M |
Shares outstanding 29.7M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.